Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Outsourcing
Bachem, Lilly partner on oligonucleotide drugs
by Rick Mullin
April 30, 2022
| A version of this story appeared in
Volume 100, Issue 15
Credit: Bachem
Bachem says oligos can act on drug targets that are not accessible with small-molecule or biologic drugs.
Bachem and Eli Lilly and Company have formed a collaboration aimed at developing and manufacturing active pharmaceutical ingredients (APIs) based on oligonucleotides. Under the terms of the agreement, Bachem will provide R&D services and manufacture APIs at its plant in Bubendorf, Switzerland, using Lilly’s oligonucleotide technology. The 7-year deal has the potential to net Bachem about $100 million per year.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X